Department of Radiation and Medical Oncology, Hubei Province Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China.
Department of Gastrointestinal Surgery & Department of Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, 518020, People's Republic of China.
Int J Nanomedicine. 2024 Jan 15;19:403-414. doi: 10.2147/IJN.S445805. eCollection 2024.
Radiotherapy is an indispensable part of the multidisciplinary treatment of breast cancer (BC). Due to the potential for serious side effects from ionizing radiation in the treatment of breast cancer, which can adversely affect the patient's quality of life, the radiation dose is often limited. This limitation can result in an incomplete eradication of tumors.
In this study, biomimetic copper single-atom catalysts (platelet cell membrane camouflaging, PC) were synthesized with the aim of improving the therapeutic outcomes of radiotherapy for BC. Following guidance to the tumor site facilitated by the platelet cell membrane coating, PC releases a copper single-atom nanozyme (SAzyme). This SAzyme enhances therapeutic effects by generating reactive oxygen species from HO and concurrently inhibiting the self-repair mechanisms of cancer cells through the consumption of intracellular glutathione (GSH) within the tumor microenvironment. PC-augmented radiotherapy induces immunogenic cell death, which triggers an immune response to eradicate tumors.
With the excellent biocompatibility, PC exhibited precise tumor-targeting capabilities. Furthermore, when employed in conjunction with radiotherapy, PC showed impressive tumor elimination results through immunological activation. Remarkably, the tumor suppression rate achieved with PC-enhanced radiotherapy reached an impressive 93.6%.
Therefore, PC presents an innovative approach for designing radiosensitizers with tumor-specific targeting capabilities, aiming to enhance the therapeutic impact of radiotherapy on BC.
放射治疗是乳腺癌（BC）多学科治疗不可或缺的一部分。由于乳腺癌治疗中电离辐射可能产生严重的副作用，这会对患者的生活质量产生不利影响，因此辐射剂量通常受到限制。这种限制可能导致肿瘤不能完全根除。
在这项研究中，合成了仿生铜单原子催化剂（血小板细胞膜伪装，PC），旨在提高乳腺癌放射治疗的疗效。在血小板细胞膜涂层的引导下，PC 释放出铜单原子纳米酶（SAzyme）。这种 SAzyme 通过产生 HO 中的活性氧并同时通过消耗肿瘤微环境中的细胞内谷胱甘肽（GSH）来抑制癌细胞的自我修复机制，增强治疗效果。PC 增强的放射治疗诱导免疫原性细胞死亡，引发免疫反应以消灭肿瘤。
PC 具有优异的生物相容性，表现出精确的肿瘤靶向能力。此外，当与放射治疗联合使用时，PC 通过免疫激活显示出令人印象深刻的肿瘤消除效果。值得注意的是，PC 增强放射治疗的肿瘤抑制率达到了令人印象深刻的 93.6%。
因此，PC 为设计具有肿瘤特异性靶向能力的放射增敏剂提供了一种创新方法，旨在增强放射治疗对 BC 的治疗效果。
